October 1, 2007
Hepalife Technologies, Inc. NAICS 541710
60 State Street, Suite 700 Boston, MA 02109 Description Biotechnology
1-800-518-4879 Employees 5
http://www.hepalife.com/ Revenue (mil) 0.0000
  Income (mil) -4.6540
  Assets (mil) 0.2790
  Liability (mil) 1.3380
  (for the year ended 2006-12-31)
Category: Loss/Deficit
Event: Hepalife Technologies, Inc. had a net loss of $802,368 for the second quarter ended June 30, 2007, lower than the $1,437,396 net loss reported during the same quarter last year. For the six months ended June 30, 2007, the Company had a $1,541,348 net loss, lower than the $2,169,835 net loss reported in the first half of 2006. The Company's balance sheet showed an accumulated deficit of $12,757,220 as of June 30, 2007.
Intellectual Property: The Company is working towards optimizing the functionality of a chicken cell line, which is called the “PBS-1 Cell Line.” The PBS-1 Cell Line was developed for use in cell-based vaccine production and was exclusively licensed from the Michigan State University in June 2006. The license agreement gives HepaLife exclusive rights to five issued patents. [SEC Filing 10-K 04-02-07]
Description: The Company focuses on the identification and development of technologies and products for liver toxicity detection; products for the treatment of various forms of liver dysfunction and disease; and cell based technologies vaccine production.
Officers: Harmel S. Rayat (Chair, Sec., Treas. & CFO); Frank Menzler (Pres. & CEO); Javier Jimenez (Dir.)
Auditor: Peterson Sullivan PLLC
Securities: Common Stock-Symbol HPLF.OB; OTC BB; 73,926,276 common shares outstanding as of August 15, 2007.
return to main page